TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04663815

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Animal-assisted activity
Description: The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Animal-assisted activity
Description: The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Control intervention
Description: The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Control intervention
Description: The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
Study: NCT05360238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.
Study: NCT05829408

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: KOPPeling
Description: KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: KOPPeling
Description: KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
Study: NCT05946993

Intervention type: OTHER
Group type: OTHER
Intervention: Dietitian Support
Description: The main goal of the nutritional intervention is to improve the diet quality of each patient using a standardized nutrition assessment, offering evidence-based diet group education and developing personalized nutrition goals. Participants will be progressively guided through the nutrition education programme; with modifications to the individual's usual diet, thereby recognizing personal eating patterns and preferences, which form the basis for individualized dietary counselling. The dietary counselling identifies the type, amount, and frequency of feeding and specifies the caloric/protein level to attain, together with any restrictions and limited or increased individual dietary components.

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing and Psychosocial
Description: Nursing, Psycho-oncology, pastoral care and social work-led sessions to inform participants on items including diagnosis shock, acceptance, coping with relationship changes with their partner and their roles, fear of uncertainty and the future, medication management, masculinity (male values being strong, capable, independent), practical management of bills, and household tasks. There will be an inclusion of practical information sessions including health systems information and managing side effects such as urinary symptoms, hot flushes, penile shortening, and loss of body hair.
Study: NCT05928325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete geriatric assessments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive survivorship care education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracking device
Study: NCT05873075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Description: Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
Study: NCT06010953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS109
Description: on-demand treatment with SS109 at the time of a new hemorrhage event

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS109
Description: on-demand treatment with SS109 at the time of a new hemorrhage event
Study: NCT05928325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive geriatric assessment-guided interventions
Study: NCT06347185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early palliative care, integrated with the standard oncologic care (proactive approach)
Description: Besides the Oncology visit, patient will have the palliative care expert visit and follow up (proactive approach). The oncologist will define the therapeutic approach and the assessments requested, in terms of type of exams and timing. The palliative care clinician and the oncologist will judge the burden of symptoms and together they will propose the suggested interventions to relief the symptoms, with a particular attention to the Liverpool Head and Neck Patient Concern Inventory (PCI-H\&N) and patient priority questionnaire's results.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)
Description: The oncologist will be the main referral of the patient, deciding the therapeutic approach, the assessments requested, in terms of type of exams and timing and the need of possible further support from other expertise (reactive approach). The oncologist will base the choices also upon the results of the PCI-H\&N and the patient's preferences. At the end of the first oncological visit, the physician will be asked to predict the survival of the patient.
Study: NCT05359640

Intervention type: OTHER
Intervention: quality of pain
Description: We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
Study: NCT06325098

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-nephrin antibodies
Description: Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
Study: NCT06325098

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-nephrin antibodies
Description: Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: u-RPC cultures
Description: Urine sample collection for u-RPC cultures
Study: NCT05779046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT 1:1
Description: The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT 1:2
Description: The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
Study: NCT06535815

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)
Description: 12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
Study: NCT05218252

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior interosseous artery flap
Description: The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
Study: NCT06268912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Mepivacaine
Description: change the temperature, 3% at 5ºC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine at room temperature
Description: no change the temperature of anesthesia
Study: NCT06004700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: The current app contains a disease activity questionnaire, a mood scale, a sleep scale, a pain scale, and a functional status scale. The app triggers a brief set of questions each day and allows patients to answer them within 24 hours.
Study: NCT05072145

Intervention type: OTHER
Intervention: Telemedicine
Description: Receiving care in a tele-ED hospital
Study: NCT05308576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: D0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D0; intramuscular injection
Study: NCT05130086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: 60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
Study: NCT05675072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB2001 placebo
Description: FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
Study: NCT05831267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrin Glue
Description: Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PRF
Description: The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.

Intervention type: OTHER
Group type: OTHER
Intervention: Negative control
Description: this group will not receive any material.
Study: NCT05187377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Growth hormone will be administered subcutaneously once daily. A starting dose of 0.15 mg/kg/week divided daily for 2 weeks to ensure safety and tolerance. The dose will then be increased to 0.3 mg/kg/week for 10 weeks. Doses will be titrated based on IGF-1 levels and monitored every four weeks up to a maximum dose of 0.45 mg/kg/week based on the package insert.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo (saline) will be administered subcutaneously once daily.
Study: NCT06536075

Intervention type: RADIATION
Group type: OTHER
Intervention: Sialoscintigraphy
Description: Sialoscintigraphy

Intervention type: RADIATION
Group type: OTHER
Intervention: Sialoscintigraphy
Description: Sialoscintigraphy
Study: NCT05194826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test
Description: immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
Study: NCT04719572

Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment group
Description: A total of 60 subjects were recruited in the group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment group
Description: A total of 60 subjects were recruited in the group.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment+ anti-osteoporosis drug group
Description: A total of 60 subjects were recruited in the group.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment+ anti-osteoporosis drug group
Description: A total of 60 subjects were recruited in the group.

Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment + non-drug treatment group
Description: A total of 60 subjects were recruited in the group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment + non-drug treatment group
Description: A total of 60 subjects were recruited in the group.
Study: NCT06351891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline
Description: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
Description: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
Study: NCT06489808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib RP2D D1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib RP2D D1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m2 D0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m2 D0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine per regimen dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine per regimen dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5g/m2 D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100mg/m2 D1-3
Study: NCT06392321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: comparison between bupivacaine, bupivacaine and fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparison between bupivacaine, bupivacaine and dexmedetomidine..
Study: NCT06489808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg D1-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 D1, continuous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Ara-C 2g/m2 q12h D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Mitoxantrone hydrochloride liposome 18mg/m2 D1
Study: NCT05857046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 10 MG
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
Study: NCT05517343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time endoscopic optical diagnosis
Description: The participants assigned to real-time notification group will received the endoscopic diagnosis of the resected colorectal polyps and recommended surveillance colonoscopy schedule right after the sedated colonoscopy.
Study: NCT06193993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
Study: NCT05360524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy alone versus laminectomy and fusion
Description: laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laminectomy alone versus laminectomy and fusion
Description: laminectomy only with expected less operative time, blood loss and restriction of neck motion (compared to laminectomy with fusion). Instrumented fusions also entail the risks of screw misplacement, pseudoarthrosis, distal junction kyphosis, and adjacent segment pathology.~Multi-level laminectomy compromises the posterior tension band and increases the mobility of the neck, resulting in post laminectomy kyphosis and potential dynamic injury to the spinal cord . In contrast, spinal instrumentation and fusion helps to eliminate movement at the treated levels and reduce spinal cord tension with less incidence of kyphosis.
Study: NCT04982042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
Study: NCT04858737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-predictD-Work intervention
Description: The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychoeducational messages
Description: The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
Study: NCT05178628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innohep
Description: Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy: Gemcitabine + Nab-Paclitaxel
Description: All patients will receive chemotherapy per clinical practice